IBS C News and Research

RSS

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Nerve growth factor may be dynamic marker of OAB pathophysiology

Urine levels of nerve growth factor fluctuate in line with changes in bladder pathophysiology, a 5-year study of people with overactive bladder has found.

10 Mar 2014

Findings suggest that IBS is linked to detectable gut microbiota alterations

Irritable bowel syndrome (IBS) belongs to the most widespread diseases in Western countries, causing up to sixty per cent of the workload of gastrointestinal physicians. One of the most frequent symptoms of IBS is bloating, which reduces quality of life considerably as patients perceive it as particularly bothersome.

10 Mar 2014

Furiex announces top-line results of Phase III clinical trials of eluxadoline in treatment of IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.

4 Feb 2014

New, "designer" dietary fiber may eliminate side effects of current IBS treatment

A newly-developed, "designer" dietary fiber with an added potential prebiotic effect may eliminate the side effects of current treatment for Irritable Bowel Syndrome which affects 10-20 percent of the population, disproportionately women.

20 Jan 2014

Nottingham scientists use MRI technology to assist in treatment, diagnosis of irritable bowel syndrome

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome (IBS), a condition that causes serious inconvenience and discomfort to sufferers.

10 Jan 2014

Nottingham scientists exploit MRI technology to assist in the treatment of IBS

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome, a condition that causes serious inconvenience and discomfort to sufferers.

9 Jan 2014

Applied BioCode signs License and Supply Agreement with Genetic Analysis for BMB technology

Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead technology with Genetic Analysis of Oslo, Norway.

7 Jan 2014

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

Studies offer new insight into diverticulosis

Diverticulosis, a condition that develops when pouches form in the wall of the colon, is increasing in frequency. It affects the majority of those reaching the age of 80 - a growing portion of the population - and imposes a substantial burden on health-care resources, but curiously there is a lack of data and unanswered questions around this condition.

18 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Researchers develop simple blood test to identify patient with Irritable Bowel Syndrome

For the first time, a simple blood test may be the best way to determine if a patient is suffering from Irritable Bowel Syndrome, or another serious condition such as Inflammatory Bowel Disease, according to Cedars-Sinai physician researcher Mark Pimentel, MD, lead author of a multicenter clinical trial.

17 Oct 2013

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care.

15 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

UCLA researchers explain Post-Diverticulitis Irritable Bowel Syndrome

UCLA researchers have described a new form of irritable bowel syndrome that occurs after an acute bout of diverticulitis, a finding that may help lead to better management of symptoms and relief for patients.

6 Sep 2013

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.

16 Jul 2013

Constella® (linaclotide), for the symptomatic treatment of Irritable Bowel Syndrome with Constipation (IBS-C), is now available in Germany, UK and Nordic countries

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

13 Jun 2013